News

University of Calgary’s Hotchkiss Brain Institute will utilize the funds to study the damage that occurs in MS prior to inflammation. To date, central nervous system (CNS) damage

ELND005 is used in the treatment of neuropsychiatric disorders such as Alzheimer’s and bipolar. The company plans to initiate a proof of concept, Phase II study in bipolar

The open-label, multinational, Phase 2 clinical study is designed to assess the safety and tolerability of infusions of GALNS at a dose of 2.0 mg/kg/week over a 52-week

Travelan, an over the counter (OTC) product, is used for the prevention of Travellers Diarrhea, by reducing the risk of infection by ETEC, the most common cause of

Rilpivirine is a non-nucleoside reverse transcriptase inhibitor (NNRTI), which blocks reverse transcriptase, a key enzyme that is used by the HIV virus to replicate. The marketing authorisation of

IPI-145 by Infinity is a potent, oral inhibitor of phosphoinositide-3-kinase (PI3K) delta and gamma, used in the treatment of hematologic cancers and inflammatory conditions. IPI-145 is currently undergoing

Lodotra, used in the treatment of rheumatoid arthritis (RA), is a programmed-release formulation of low dose prednisone, that is developed using SkyePharma’s Geoclock technology in collaboration with Horizon.

Huron Life Sciences’ Click Portal software is believed to help re-engineer specific processes, streamline information flows, provide accurate detailed budgets, and eliminate billing inconsistencies. The new software will

Cabozantinib is a potent, dual inhibitor of MET and VEGFR2. Exelixis and the NCI will carry out a series of clinical trials to assess the safety and efficacy